Kisspeptin-10 and the HPG axis: the human evidence

Key takeaways

• Kisspeptin is encoded by KISS1 and signals through KISS1R (formerly GPR54). It is the upstream activator of GnRH neurons in the hypothalamic arcuate and preoptic nuclei. Loss-of-function KISS1R variants cause normosmic hypogonadotropic hypogonadism in humans, which established the pathway's clinical importance .
• The kisspeptin family includes the parent kisspeptin-54 (KP-54), kisspeptin-14 (KP-14), kisspeptin-13 (KP-13), and the C-terminal decapeptide kisspeptin-10 (KP-10). All four share the same C-terminal RF-amide motif that activates KISS1R, but they differ substantially in circulating half-life .
• The published human trial literature is dominated by KP-54, used at the Imperial College London program of Dhillo, Abbara and Jayasena and the Edinburgh program of Skorupskaite and Anderson. Kisspeptin-54 has been used investigationally as an ovulation trigger in IVF, as a probe of hypothalamic amenorrhea, and as a tool for studying GnRH pulse generation .
• Kisspeptin-10 has a very short circulating half-life (minutes), which is why the human trial program preferentially uses KP-54 for sustained dosing. Research-vial KP-10 product sold to the community is not the peptide that the IVF trigger trials used and is not interchangeable with KP-54 by dose .
• No kisspeptin product is FDA-approved, and in October 2024 an FDA advisory committee voted against adding kisspeptin-10 to the 503A bulk-substances list for compounding . Research-vial kisspeptin falls under the FDA's bulk-substances safety-risk posture, and its identity and dose accuracy cannot be assumed .

What kisspeptin is and how it was discovered

KISS1 was originally identified in 1996 as a metastasis suppressor gene in melanoma. The peptide product was named for the town of Hershey, Pennsylvania, where the discovering laboratory worked and the famous Hershey's Kisses chocolate was made. The reproductive role of kisspeptin emerged later, when independent groups reported that loss-of-function variants in GPR54 (now KISS1R) caused hypogonadotropic hypogonadism in human pedigrees. That established kisspeptin as the missing upstream activator of GnRH neurons .

In the current model, kisspeptin neurons in the arcuate nucleus generate the pulse pattern of GnRH release through coordinated firing, integrating estrogen and androgen feedback. Kisspeptin neurons in the anteroventral periventricular nucleus mediate the preovulatory LH surge in females. KISS1R activation on GnRH neurons triggers GnRH release into the hypophyseal portal system, which drives LH and FSH release from the anterior pituitary. The downstream gonadal axis follows from that signal.

KP-54 versus KP-10: why the literature uses one and the community uses the other

The parent peptide kisspeptin-54 (KP-54) is the 54-residue mature form processed from the KISS1 precursor. Shorter forms (KP-14, KP-13, KP-10) share the C-terminal RF-amide that contains the receptor-binding motif. In receptor assays, all of these fragments activate KISS1R with similar intrinsic potency. The clinical difference is half-life and exposure shape .

Kisspeptin-10 clears fast. In a direct in vivo comparison in mice, its circulating half-life was about 4 minutes, against about 32 minutes for kisspeptin-54 . A bolus of KP-10 drives a sharp, short LH response, which is useful for probing single GnRH pulses but inconvenient for sustained dosing. Kisspeptin-54 is the longer-acting form: a single subcutaneous KP-54 injection raises LH and FSH for hours in humans, which makes it tractable for sustained activation in a controlled trial setting, and most of the human trial program uses KP-54 for that reason .

• Trial protocols for IVF triggers, hypothalamic amenorrhea probes, and pubertal-axis stimulation typically use kisspeptin-54 (KP-54).
• Mechanism-of-action and single-pulse studies often use kisspeptin-10 (KP-10) intravenously in a research setting.
• Research-vial peptide product sold as KP-10 to the community is not the same molecule as the KP-54 used in the published efficacy trials.
• Equivalence between KP-10 doses and KP-54 doses is not established. Dose conversion based on receptor potency alone ignores the exposure-shape difference.

What the human trial program has actually shown

The Imperial College London group around Waljit Dhillo and Ali Abbara has run the most consistent human kisspeptin trial program. The 2005 first-in-human work (Dhillo WS, Chaudhri OB, Patterson M, et al., Journal of Clinical Endocrinology and Metabolism) showed that intravenous KP-54 in healthy men raised circulating LH and FSH, establishing the human pharmacology of the upstream pathway .

Subsequent work explored kisspeptin in women across the menstrual cycle, in women with functional hypothalamic amenorrhea, and in IVF cycle triggering. The Abbara 2015 paper (Journal of Clinical Endocrinology and Metabolism) used kisspeptin-54 as the ovulation trigger in women at high risk of ovarian hyperstimulation syndrome, reporting oocyte maturation in 95 percent of women, no moderate-to-critical OHSS, and live births, which framed kisspeptin as a candidate alternative to hCG triggering .

Edinburgh-based work by Karolina Skorupskaite, Richard Anderson and colleagues has used kisspeptin to probe GnRH pulse generation across reproductive phases and in the context of hypothalamic amenorrhea. Those studies are mechanism-rich rather than efficacy-focused; they map how the kisspeptin signal interacts with neurokinin B and dynorphin (the KNDy neuron network) to set the GnRH pulse pattern .

What KP-10 actually does in research protocols

Kisspeptin-10 is the typical peptide used when investigators need a sharp, short LH response in a research setting. Its short half-life gives a transient rise that suits single-pulse experiments, GnRH-neuron-stimulation probes, and acute mechanism-of-action work. It is poorly suited to sustained physiological replacement, which is the use case for KP-54 .

Community use of subcutaneous KP-10 as a long-acting libido or fertility-supporting peptide is not supported by the pharmacokinetic literature. Subcutaneous bioavailability and half-life of KP-10 have not been characterized to label-grade standards, and the IVF-trigger and amenorrhea trial data the community cites in defense of KP-10 protocols was generated with KP-54, a different peptide. The accurate description of KP-10 is a research probe for single-pulse pharmacology. No human dataset shows it works as a sustained-activation therapy given subcutaneously.

What kisspeptin therapy is not (yet)

• Not an FDA-approved product. No kisspeptin label, no KP-10 label, no KP-54 label.
• Not a documented standalone fertility treatment outside registered trial protocols.
• Not a documented testosterone-replacement strategy. The HPG-axis activation hypothesis is plausible mechanistically, but no Phase 3 trial supports kisspeptin as a primary therapy for male hypogonadism.
• Not an approved libido drug. A randomized trial from the Imperial College group did find intravenous kisspeptin-54 modulated sexual brain processing and raised penile tumescence by 56 percent over placebo in men with hypoactive sexual desire disorder, but that is early human mechanism work, not a marketed sexual-health treatment .
• Not interchangeable across fragments. KP-10 and KP-54 are pharmacokinetically distinct, and trial data on one does not automatically extend to the other.

Regulatory and research-vial context

Kisspeptin-10 and kisspeptin-54 are both investigational worldwide. The FDA's posture on peptide bulk substances applies to research-vial kisspeptin sold to the community; identity, purity, and dose accuracy of those preparations cannot be assumed from the published trial literature, which used regulated investigational supply with characterized analytical certificates . In October 2024 the FDA's Pharmacy Compounding Advisory Committee reviewed kisspeptin-10, which had been nominated for compounding to treat secondary hypogonadism in men, and voted against adding it to the 503A bulk-substances list, citing limited safety and effectiveness data and no approved kisspeptin product anywhere in the world .

The honest read on kisspeptin-10

Kisspeptin is a real human pathway with a real, growing trial literature, and the KP-54 IVF-trigger and hypothalamic-amenorrhea work is the credible part of it. The catch for anyone buying research-vial KP-10 is that the decapeptide in the vial is not the peptide those trials ran, no version of the molecule is approved anywhere, and dose equivalence between the fragments has never been established. That gap between trial peptide and vial peptide is where community hype outruns the evidence, and no receptor-potency argument closes it.

For research and educational purposes only. Not medical advice.

pepSmart has not commissioned independent clinical review of this article.

More on how we write and source these pieces: Editorial process and contributor disclosure and Sourcing posture.

Spot an error? Email corrections via /about.

Sources: 10 entries, all primary canon (PubMed clinical trials and reviews, an FDA compounding safety-risk page, and an FDA advisory-committee record), last reviewed 2026-07-08.

Related tools

• Protocol builder overview - Public overview of the Pro protocol builder.
• Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.
• BAC water calculator - Solve BAC water volume for a target concentration.
• Multi-dose vial calculator - Estimate doses per vial and a projected vial-empty date.
• Reconstituted-vial storage window calculator - Estimate a generic usable-window date and days remaining.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.